on EV Nickel Inc. (isin : DE000A3CMGM5)
APONTIS PHARMA's Boards Recommend Acceptance of Zentiva's Tender Offer
The Management and Supervisory Boards of APONTIS PHARMA AG have advised shareholders to accept a tender offer from Zentiva AG. The offer is priced at EUR 10.00 per share, representing a 52.9% premium against the closing price on October 15, 2024, and a 38.3% premium to the three-month volume-weighted average.
Both boards believe the financial terms are favorable and the agreement supports APONTIS PHARMA's growth strategy. Zentiva’s bid seeks to enhance APONTIS PHARMA's resource availability and product range. The acceptance deadline for the offer is set for November 21, 2024.
By partnering with Zentiva, APONTIS PHARMA anticipates bolstering its research, development, and commercialization opportunities across Europe, which is deemed vital for the company's long-term success.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EV Nickel Inc. news